Top Markets
#1 Cortex Cortex +173.61%
#2 GEKKO GEKKO +53.94%
#3 Audiera Audiera +19.71%
#4 ADO Protocol ADO Protocol +17.93%
#5 TENDIES TENDIES +15.98%
#6 Ontology Gas Ontology Gas +15.75%
#7 Pons Pons +15.23%
#8 Siren Siren +13.26%
#9 o1.exchange o1.exchange +12.90%
#10 Helium Helium +12.27%
Coin of the day
Cortex Cortex
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Sopharma AD Sopharma AD

Sopharma AD

SPH
Peringkat dalam Saham #8637
Sopharma AD, an international pharmaceutical company founded in Sofia,... Sopharma AD, an international pharmaceutical company founded in Sofia, Bulgaria, in 1933, specializes in the research, development, manufacturing, and commercialization of a wide array of healthcare products. Its offerings span medicinal substances, finished drug formulations, veterinary vaccines, infusion solutions, and disposable plastic medical devices for both human and animal health, in addition to food supplements. The company's diverse product portfolio addresses numerous therapeutic categories, including cardiology, gastroenterology, pain management, cough and cold remedies, immunology and dermatology, respiratory conditions (like asthma), neurology and psychiatry, urology, and gynecology. Key products include Carsil for gastrointestinal issues, the analgesic Tempalgin, Tabex for smoking cessation, Tribestan to support sexual system functions, Broncholytin for coughs, the common pain reliever Analgin, Nivalin for peripheral nervous system disorders, and Methylprednisolon for severe allergies and critical medical situations. Beyond its core pharmaceutical business, Sopharma AD engages in a variety of other ventures. These include providing secondary packaging services for pharmaceuticals, leasing real estate, and operating in the retail sector for medicines and medical equipment. The company also handles the cultivation, collection, and trade of herbs and medicinal plants. Furthermore, it is involved in the trading, transport, and packaging of radioactive materials and nuclear equipment for medical applications, as well as household electronics and electrical equipment. Sopharma AD also offers market and public opinion research, provides franchising and know-how, and participates in various consulting and non-pharmaceutical activities, such as the production of veterinary vaccines and infusion solutions.
Harga Saham
$2.28
Terakhir disinkronkan: 2026-08-27
Kapitalisasi Pasar
$1.20B
Perubahan (1 hari)
2.53%
Perubahan (1 tahun)
-34.74%
Negara
BG
Perdagangan Sopharma AD (SPH)

Kategori

Healthcare
Rasio P/E untuk Sopharma AD (SPH)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Sopharma AD, rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk Sopharma AD dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
McKesson Corporation McKesson Corporation
McKesson Corporation
MCK.US
 23.15 -
US
Cencora, Inc. Cencora, Inc.
Cencora, Inc.
COR.US
 - -
US
Cardinal Health, Inc. Cardinal Health, Inc.
Cardinal Health, Inc.
CAH.US
 32.35 -
US
AmerisourceBergen Corporation AmerisourceBergen Corporation
AmerisourceBergen Corporation
ABC.US
 - -
US
Sigma Healthcare Limited Sigma Healthcare Limited
Sigma Healthcare Limited
SIG.AX
 -338.64 -
AU
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.